首页> 美国卫生研究院文献>Case Reports in Nephrology and Dialysis >Rituximab Treatment in a Patient with Kimura Disease and Membranous Nephropathy: Case Report
【2h】

Rituximab Treatment in a Patient with Kimura Disease and Membranous Nephropathy: Case Report

机译:Rituximab在患有Kimura病和膜肾病的患者中治疗:案例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Kimura disease (KD) is a chronic, inflammatory disorder with slowly developing subcutaneous tumor-like swellings, often occurring in the head and neck region. KD is diagnosed based on histology, elevated levels of immunoglobulin type E, and increased peripheral eosinophil granulocytes. KD may coexist with glomerular renal diseases, and this case report is based on a patient with KD-associated membranous nephropathy. Patients with membranous nephropathy without KD have demonstrated responsiveness to treatment with monoclonal anti-CD20 antibodies. This case report is the first to investigate the effect of rituximab treatment in a patient with KD-associated membranous nephropathy. A 30-year-old Italian man living in Denmark was diagnosed with Kimura's disease based on subcutaneous nodules with eosinophil angiolymphoid hyperplasia. The patient was admitted to the hospital due to nephrotic syndrome. Serology showed eosinophil granulocytosis and negative PLA2-receptor antibody. Renal biopsy showed membranous nephropathy, and the patient was treated with systemic methylprednisolone followed by cyclosporin and then cyclophosphamide with only partial remission. Ultimately, treatment with intravenous rituximab was initiated, which resulted in overall remission and no nephrotic relapses at 30 months of follow-up. Thus, intravenous rituximab effectively decreased proteinuria and prevented nephrotic relapses in a patient with treatment-refractory membranous nephropathy due to KD.
机译:Kimura疾病(KD)是一种慢性炎症性疾病,慢慢发展皮下肿瘤状肿胀,通常发生在头部和颈部区域。基于组织学,升高的免疫球蛋白型E和外周嗜酸性粒细胞粒细胞增加,KD被诊断。 KD可能与肾小球肾病共存,并且本病例报告基于患有KD相关膜肾病的患者。没有KD的膜肾病患者已经证明了用单克隆抗CD20抗体治疗的反应性。本病例报告是首先调查利妥昔单抗治疗在患有KD相关膜肾病的患者中的效果。一名居住在丹麦的30岁的意大利人被诊断为基于皮下结节的Kimura病,具有嗜酸性粒细胞angiol ymphoid增生。由于肾病综合征,患者被患者入院。血清学表现出嗜酸性粒细胞粒细胞症和阴性PLA2受体抗体。肾活检显示膜肾病,患者用全身甲基己酮酮处理,然后是环孢菌素,然后仅具有部分缓解的环磷酰胺。最终,启动了用静脉内Rituximab的治疗,导致总缓解,并且在30个月后没有肾脏复发。因此,静脉内蓖麻油肢体有效地降低了蛋白尿和预防由于KD的治疗 - 难治性膜肾病的患者患者的肾功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号